Heparanase-inhibiting heparin/HS-mimicking compounds, small molecules, and antibodies are being developed [14,15,16], of which several saccharide-based compounds were and/or are being examined in cancer clinical trials [17,18], yet none of the compounds reached the stage of approval for clinical use. The gene discussed is HPSE; the disease is cancer.